Endo Pharmaceuticals Up In Pre-Market On FDA Approval For Drug (ENDP)

Endo Pharmaceuticals ENDP is higher in pre-market trading by 4.8% to $36.94 after the company received FDA approval for FORTESTA. FORTESTA is a gel for men used to treat low levels of testosterone. The FDA approved it after satisfying concerns that it would rub off on children and women. Endo officials have not commented on potential U.S. sales for the drug. Endo's Fortesta will be used to treat low testosterone levels, or hypogonadism, which can be associated with erectile dysfunction, osteoporosis and hair loss. "It's important to do what one can to prevent the transfer from one person to another," Ivan Gergel, Endo's executive vice president of research and development. "Anyone using it would have to be very careful."